PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 76 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma MOST POPULAR Coronavirus and COVID-19: What People With Cancer Need to Know June 21, 2020 Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell... April 24, 2024 Revumenib Shows Promise in Treating Advanced Acute Myeloid Leukemia April 18, 2023 Professor Ian Tomlinson: “Philanthropy is priceless to science” June 3, 2021 Load more HOT NEWS New option to treat advanced oesophageal cancer approved for NHS in... Trastuzumab May Improve Survival in Women with Rare Endometrial Cancer ‘Levelling Up’: What should it mean for cancer? How to Talk About Advanced Cancer Care Planning: An Expert Discussion
